Call
+918447748545

Published on: Apr 06, 2020
2 minute read
By: Dr Rajan Choudhary

MicroRNA That Makes Them Fight COVID Better ?

Recently you may have read a New Delhi based International Center for Genetic Engineering and Biotechnology (ICGEB) sequenced the genome (genetic data) of SARS-COV-2 (coronavirus) from India, Italy, US, Nepal and Wuhan, China. They found that the Indian variant of SARS-CoV2 has the potential to be targeted by antiviral RNA within host cells, a feature that is unique to the Indian strain.

This amazing finding has been published on blogs, newspapers and other media as proof that Indians may not suffer as much as the rest of the world when the COVID-19 pandemic hits the country. One headline touted “MicroRNA in Indians may reduce severity of corona attack”, stating “Indians have comparatively better immunity compared to other countries”. Of course this article is being forwarded on WhatsApp, and enough people may take it as gospel. Is it true?

No.

If you want to know why, just look on the Journal’s website:

“these are preliminary reports that have not been peer-reviewed. They should NOT be regarded as conclusive, guide clinical practice/health-related behaviour, or be reported in news media as established information.”

Research is not easy. I could write a very long explanation for why, but I have summarised it below.

SUMMARY:

- To prove x causes y up to a high scientific standard is incredibly difficult

- Even if you think x causes y, someone might find a flaw in your study

- Numbers can be manipulated by statistics to show what you want to believe

- Reporters might not understand the study and mis-report it

- We all want to believe there is a magic cure that will protect us, that makes us special, immune to this disaster so we can get on with our lives. Unfortunately there simply isn’t one. And believing in them without fact checking can cause more harm than good.

IMMUNITY AGAINST COVID

So what about this study? Firstly it is looking at one tiny mechanism in a cell, when a cell can have millions of proteins responsible for a billion different functions in just the cell itself. Secondly it is not peer reviewed. This means no one has fact checked the study to check whether the design is valid, whether the statistics hold up, whether they have missed something or are making incorrect conclusions based off their data. Peer-reviewing a recent paper showing SARS-CoV-2 and HIV were extremely similar disproved this paper as false.

In the authors defence he acknowledges this:

“In our study, which is a purely computational one, we predicted that this microRNA binds to the SARS-Cov2 genome submitted from India. However, it is too early to comment on it because there is only one high coverage sequence from India, so far,”

Thirdly, the news article says that Indians have better immunity because of this “microRNA”. This is wrong. The study sequenced the genome of the virus, not of the Indian population. Antiviral microRNA is found in all people. The study simply suggests that this might be more effective at targeting the Indian strain of COVID, but it does not make any concrete claims that Indians are protected from COVID.

Again, the journal even states this:

“These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.”

But most importantly, even if the paper suggests that the Indian strain may be less potent, it does not give us an excuse to be reckless. We have to adhere to social distancing, hygiene, lockdown principles in order to prevent infection. Because what happens if you take the article stating “Indians have comparatively better immunity compared to other countries” as fact, use this as an excuse to go about your regular daily lives, and it actually turns out that the microRNA has little to no effect on COVID. This endangers yourself and those around you.

Be sensible. Listen to public health officials.

Dr Rajan Choudhary, UK, Chief Product Officer, Second Medic Inc

www.secondmedic.com

Read Blog

Monkeypox Virus Symptoms: Early Signs, Disease Progression, and When to Seek Care

Monkeypox, now commonly referred to as mpox, is a viral infection that has gained global attention due to outbreaks beyond traditionally affected regions. Understanding monkeypox virus symptoms is essential for early detection, timely isolation and prevention of further spread.

According to the World Health Organization and Indian public health authorities, awareness of symptom patterns plays a critical role in controlling outbreaks and protecting vulnerable populations.

What Is the Monkeypox Virus?

Monkeypox is caused by the monkeypox virus, a member of the Orthopoxvirus family, which also includes smallpox. While generally less severe than smallpox, monkeypox can still cause significant illness and discomfort.

The virus spreads primarily through close physical contact.

Incubation Period of Monkeypox

After exposure, symptoms typically appear within:

5 to 21 days
most commonly 6 to 13 days

Individuals may feel well during this period but can become infectious once symptoms begin.

Early Monkeypox Virus Symptoms

Fever

Fever is usually the first symptom and may be:

sudden in onset
moderate to high grade
accompanied by chills

Fever signals the start of systemic infection.

Headache and Body Aches

Patients often experience:

severe headache
muscle aches
back pain

These symptoms resemble many viral illnesses.

Fatigue and Weakness

Marked tiredness and low energy levels are common and may limit daily activities.

Swollen Lymph Nodes

Swollen lymph nodes are a distinguishing feature of monkeypox.

Common sites include:

neck
armpits
groin

This helps differentiate monkeypox from chickenpox or smallpox.

Development of Monkeypox Rash

The skin rash usually appears:

1 to 3 days after fever onset

It may begin on the face or genital area and spread to other parts of the body.

Stages of Monkeypox Rash

The rash progresses through well-defined stages:

Macules

Flat red spots on the skin.

Papules

Raised, firm bumps.

Vesicles

Fluid-filled blisters.

Pustules

Pus-filled lesions that are painful.

Scabs

Lesions crust over and eventually fall off.

Complete healing occurs once scabs detach.

Distribution of Rash

Rash commonly affects:

face
hands and feet
mouth
genital and anal areas

The number of lesions can vary widely.

Pain and Discomfort

Rash lesions may be:

painful
itchy during healing

Pain severity differs between individuals.

Other Possible Symptoms

Additional symptoms may include:

sore throat
cough
nasal congestion

These reflect upper respiratory involvement.

Duration of Illness

Monkeypox symptoms typically last:

2 to 4 weeks

Recovery occurs gradually as lesions heal.

Who Is at Higher Risk of Severe Illness?

Higher risk groups include:

children
pregnant women
individuals with weakened immunity
people with chronic illness

Early care is crucial in these groups.

Complications of Monkeypox

Though uncommon, complications may include:

secondary bacterial skin infections
dehydration
pneumonia
eye involvement

Prompt medical guidance reduces risk.

How Monkeypox Is Transmitted

Transmission occurs through:

direct skin-to-skin contact
contact with lesions or bodily fluids
respiratory droplets during close contact
contaminated clothing or bedding

Understanding transmission helps prevent spread.

When to Seek Medical Care

Seek medical evaluation if:

fever is followed by rash
lymph nodes become swollen
rash appears in genital or facial areas

Early diagnosis supports isolation and care.

Diagnosis and Testing

Diagnosis may involve:

clinical examination
laboratory testing of lesion samples

Public health authorities guide testing protocols.

Prevention and Control Measures

Preventive steps include:

avoiding close contact with infected individuals
maintaining good hand hygiene
isolating during illness
following public health guidance

Vaccination may be recommended for high-risk groups.

Role of Public Awareness

Awareness of symptoms:

enables early detection
reduces stigma
supports timely care

WHO emphasises community education in outbreak control.

Conclusion

Monkeypox virus symptoms typically begin with fever, body aches and swollen lymph nodes, followed by a characteristic rash that progresses through defined stages. While most cases are self-limiting, early recognition, medical evaluation and isolation are essential to prevent complications and reduce transmission. Staying informed and acting promptly protects both individual and public health.

References

World Health Organization (WHO) – Mpox (Monkeypox) Clinical and Public Health Guidance
Indian Council of Medical Research (ICMR) – Emerging Viral Infections Reports
National Centre for Disease Control (NCDC), India – Monkeypox Advisories
Lancet – Clinical Features and Outcomes of Mpox
NITI Aayog – Public Health Preparedness and Infectious Disease Control

Request A Callback

+91

By using this website/app, I confirm that I am at least 18 years old and consent to the processing of my personal data in accordance with the Terms of Service, Privacy Policy, and Declaration.